

# **Product Introduction**

## Fludarabine Phosphate

Fludarabine Phosphate is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

#### Technical Data:

Molecular Weight (MW):	365.21	HO = O = O = O = O = O = O = O = O = O =
Formula:	$C_{10}H_{13}FN_5O_7P$	
Solubility (25°C)	DMSO 73 mg/mL	
* <1 mg/ml means slightly	Water 6 mg/mL	
soluble or insoluble:	Ethanol <1 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder	
	6 months-80℃in DMSO	
CAS No.:	75607-67-9	

### **Biological Activity**

Fludarabine Phosphate is converted to F-ara-ATP in cells and then incorporated into DNA in a self-limiting manner. Fludarabine Phosphate competes with dATP for incorporation into the A site of the extending DNA strand, which results in termination of DNA strand elongation. Human DNA polymerase a incorporates more Fludarabine Phosphate into DNA than polymerase  $\delta$ . Fludarabine Phosphate completively inhibits DNA polymerase a and DNA polymerase  $\delta$  with K<sub>i</sub> of 1.1 µM and 1.3 µM, respectively. DNA polymerase  $\delta$  is also able to excise the incorporated Fludarabine Phosphate from DNA in vitro. <sup>[1]</sup>

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Fludarabine Phosphate is toxic for tumor-free mice. The maximum tolerated dose (LD10) Fludarabine Phosphate administered as a single dose is 234 mg/kg. The 50% lethal dose is 375 mg/kg. Fludarabine Phosphate administered as a single dose induces fewer number of cells surviving therapy in mice bearing P388 leukemia, accompanied by greater percentage of increase in life span (110%) and increased median survival time. <sup>[3]</sup>

#### References

- [1] Huang P, et al, J Biol Chem, 1990, 265(27), 16617-16625.
- [2] Umbach GE, et al. Invest New Drugs, 1984, 2(3), 263-265.
- [3] Avramis VI, et al. Cancer Res, 1982, 42(7), 2587-2591.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.